Health Care · Surgical & Medical Instruments & Apparatus

BBNX Beta Bionics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 167463294 filings
Russell 2000

BBNX at a glance

Beta Bionics, Inc. (BBNX, SEC CIK 1674632) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 27, 2026, an 8-K current report on October 27, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Beta Bionics, Inc. (BBNX) reported revenue of $100.3 million (up 53.9% from FY2024) and a net loss of $73.2 million. Diluted EPS was -$1.81.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Beta Bionics, Inc. (BBNX) shares worth $486.1 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Hopman Mark on November 16, 2026 of 775 shares at $16.22 per share.
  • In the last 90 days, BBNX insiders reported 0 open-market purchases ($0) and 21 open-market sales ($3.3M) on Form 4, a net sale of $3.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$100.3M
+53.9% vs prior year
Insiders · 90 days
0 buys · 21 sells
Net −$3.3M
13F holders
24 funds
$486.1M · +3 vs prior quarter
Latest 8-K
Oct 27, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $35.5M, up from $27.3M YoY, driven by higher single-use product volumes and new patient starts
  • Gross margin 57.3% vs 55.5% YoY, while net loss widened to $24.4M from $14.2M
  • Single-use products strongest line, 68% of sales vs 47%; PBP sales 38% vs 23% YoY
  • Cash, equivalents and investments $373.6M; operating cash used $50.7M, follow-on offering provided $161.8M
  • Mint launch targeted Q1 2027; FDA Warning Letter remediation, inflation, tariffs and supply risks remain headwinds

Risk Factors

  • Mint FDA clearance in September 2026 created commercialization risk, with U.S. launch targeted by end of first quarter 2027
  • 3D Intelligence 510(k) withdrawal in October 2026 delayed next-generation iLet 3D and Mint 3D plans
  • FDA Warning Letter cited Quality Management System, Medical Device Reporting, and Correction and Removals deficiencies
  • September 2026 securities class action alleges federal securities-law violations concerning iLet safety, efficacy, and commercial success
  • September 2026 follow-on offering raised net proceeds of approximately $161.3 million, but additional capital may still be required

AI summary of the BBNX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 27, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $35.5M, up 30% YoY, driven by PBP sales of $13.6M, up 118%
  • Gross margin 57.3%, while operating loss widened to $26.6M and adjusted EBITDA loss to $18.9M

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter results for period ended September 30, 2026 announced
  • Press release contains the company’s financial performance details and management commentary
Filed Sep 17, 2026Full analysis →

Item 8.01: Other Events

  • $150.0M gross public offering, comprising 7,652,175 common shares and pre-funded warrants for 1,043,484 shares
  • $17.25 per share offering price, with $0.0001 exercise price on pre-funded warrants

Item EX-99.1: Item EX-99.1

  • Proposed $125.0 million underwritten common-stock offering, subject to market conditions and completion risk
  • Potential $18.75 million additional shares through underwriters’ 30-day option

Item EX-99.2: Item EX-99.2

  • Public offering priced at $17.25 per share, targeting $150.0 million gross proceeds
  • Issuance includes 7,652,175 shares and pre-funded warrants for 1,043,484 shares, creating dilution for existing holders
Filed Sep 15, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • FDA clearance for Mint enables U.S. commercialization, targeted for Q1 2027 through the pharmacy channel
  • 2027 manufacturing capacity targets at least 1.5 million disposable units, supporting potential scale-up

Item 8.01: Other Events

  • FDA-cleared Mint expands Beta Bionics’ commercial platform, with U.S. launch targeted for Q1 2027
  • Planned 2027 capacity of at least 1.5 million disposable units supports potential scale, but execution remains unproven

Item 7.01: Regulation FD Disclosure

  • FDA clearance for Mint patch pump, enabling potential U.S. commercialization
  • 510(k) submission for 3D Intelligence dosing algorithm, advancing regulatory review

Item EX-99.2: Item EX-99.2

  • Q2’26 net sales $32.0M, gross margin 59.0%, with 69% of new starts from MDI patients
  • High-30s% of Q2’26 new starts reimbursed through pharmacy, validating Beta Bionics’ lower-friction distribution strategy

AI summaries of BBNX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BBNX

Don't miss the next BBNX filing

  • Alerts as it files. A push when BBNX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BBNX, by share count.
  • Ask anything. An AI agent that reads every BBNX filing and answers with sources.

BBNX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Hopman MarkMNov 16, 2026-
Hopman MarkSellNov 16, 2026$16.22
Hopman MarkMNov 16, 2026$5.10
Feider StephenMNov 11, 2026$5.10
Feider StephenMNov 11, 2026-
Feider StephenSellNov 11, 2026$17.21
Feider StephenMNov 9, 2026-
Feider StephenSellNov 9, 2026$17.00

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$65.1M$100.3M
Gross Profit-$35.9M$55.5M
Operating Income--$45.3M-$71.7M
Net Income--$54.8M-$73.2M
Gross Margin-55.1%55.4%
Op. Margin--69.5%-71.5%
Net Margin--84.1%-73.0%
Balance Sheet
Total Assets$110.0M$149.6M$328.7M
Equity--$245.4M$287.6M
ROE-22.3%-25.5%
Per Share
EPS$-8.31$-8.60$-1.81
Cash Flow
Operating CF--$48.3M-$50.9M
CapEx-$3.4M$5.3M

Source: XBRL data in Beta Bionics, Inc. (BBNX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BBNX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BBNX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$486.1M
Q2 202621$225.5M
Q1 202623$124.6M
Q4 202523$418.5M
Q3 202521$255.2M
Q2 202523$102.9M
Q1 202517$43.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 152 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BBNX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 13, 2026--
4Nov 12, 2026--
4Nov 9, 2026--
4Nov 4, 2026--
4Oct 29, 2026--
4Oct 28, 2026--
8-KOct 27, 2026Analysis-
10-QOct 27, 2026Analysis
4Oct 16, 2026--
4Oct 5, 2026--
4Sep 23, 2026--
4Sep 18, 2026--
8-KSep 17, 2026Analysis-
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 15, 2026--
8-KSep 15, 2026Analysis-
4Sep 10, 2026--
4Sep 4, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--

Related Health Care companies

All Health Care →

BBNX SEC filings: frequently asked questions

Are BBNX insiders buying or selling?

In the last 90 days, Beta Bionics, Inc. (BBNX) officers, directors and 10% owners reported no open-market purchases and 21 open-market sales worth $3.3 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold BBNX stock?

As of September 30, 2026, the largest Beta Bionics, Inc. (BBNX) holders among the 13F filers tracked by SignalX were T. Rowe Price Group ($169.7 million), Morgan Stanley ($82.2 million), BlackRock ($64.8 million), Vanguard Capital Management LLC ($42.5 million), JPMorgan Chase & Co ($36.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BBNX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Beta Bionics, Inc. (BBNX) reported revenue of $100.3 million (up 53.9% from FY2024) and a net loss of $73.2 million. Diluted EPS was -$1.81. The figures come from the XBRL data in the 10-K.

What did BBNX report in its latest 8-K?

Beta Bionics, Inc. (BBNX) filed an 8-K on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $35.5M, up 30% YoY, driven by PBP sales of $13.6M, up 118%.

What are the latest BBNX SEC filings?

Beta Bionics, Inc. (BBNX) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 27, 2026, an 8-K current report on October 27, 2026 and a Form 4 insider filing on November 18, 2026.

What is BBNX's SEC CIK number?

Beta Bionics, Inc. (BBNX)'s SEC Central Index Key (CIK) is 1674632. EDGAR lists every BBNX filing under that number.

Ask anything about BBNX

The research agent reads BBNX's filings, financials, insider trades and 13F holders, then answers with sources.